


MONEY & MARKETS (/MONEY-MARKETS)

Hedge Fund Manager Kyle Bass Is Going After Big Pharma And Their 'BS Patents'

JULIA LA ROCHE (/AUTHOR/JULIA-LA-ROCHE)

JAN 8, 2015, 2:47 AM

(/KYLE-BASS-GOING-AFTER-US-PHARMA-2015-1#COMMENTS)



(<http://static.businessinsider.com/image/548...>)

Kyle Bass, founder and principal of Hayman Capital Management, L.P., speaks at the Sohn Investment Conference in New York, May 8, 2013.

27) 27%20(VIA% 27&SUMMARY=TEXAN+HEDG
20@BUSINSIDERAU)) 2C+ACCORDING+TO+%
40FINANSAKROBAT%

NBS EX 2022

Texan hedge fund manager Kyle Bass is going activist against the U.S. pharmaceutical industry and their patents, according to @finansakrobat's Twitter feed (<https://twitter.com/finansakrobat>).

“We’ll have a separate pharmacy vehicle. We’ve dedicated half of our resources over the past six months to this,” Bass told conference attendees.

Bass, the founder of Hayman Capital, was speaking at the Skagen New Year’s Conference in Copenhagen (<https://www.skagenfunds.ie/Ask-us/New-Years-Conference/New-Years-Conference-2015/New-Years-Conference-2015-in-Copenhagen/>).

Bass told conference attendees that he plans to file IPR petitions (inter partes reviews (http://www.uspto.gov/aia_implementation/) to challenge drugmaker patents.

“This will change the way pharma companies [manage] their BS patents,” Bass said, according to @finansakrobat.

We reached out to Hayman Capital for more on the presentation.

In the meantime, here's a great rundown
courtesy of @finansakrobat's Twitter feed.
(<https://twitter.com/finansakrobat>)

Kyle Bass: "The US has a drug problem"
pic.twitter.com/UovzTzdeKi
(<http://twitter.com/finansakrobat/status/5528284>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528284>)

pic.twitter.com/N8zBSUCM4J
(<http://twitter.com/finansakrobat/status/5528287>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528287>)

pic.twitter.com/G8HWSxBscW
(<http://twitter.com/finansakrobat/status/5528288>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528288>)

Kyle Bass: "The mechanism on how the
US allows the pharmacy prices and how
it's all about to change"
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528291>)

pic.twitter.com/BN95059CgP
(<http://twitter.com/finansakrobat/status/552>
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528292>

pic.twitter.com/pv0N19BAjo
(<http://twitter.com/finansakrobat/status/552>
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528293>

“Only 1 of 12 cancer drugs approved in
the last year prolongs life more than 2
months”
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528295>

Kyle Bass is spitting fire. Talking about
how horrible the US Parma market is.
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528297>

pic.twitter.com/HciFvQsX4W
(<http://twitter.com/finansakrobat/status/552>
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528298>

Kyle Bass: “Bush, Hazard and Rove did a deal with the devil on Medicare D”
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528303>)

pic.twitter.com/eg61jEIGYh
(<http://twitter.com/finansakrobat/status/5528311>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528311>):

If Kyle Bass is right in that “this will change”, it’s hugely bearish for big pharma
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528313>)

pic.twitter.com/YSoHjgUG5j
(<http://twitter.com/finansakrobat/status/5528314>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528314>)

pic.twitter.com/MnioHoDxTl
(<http://twitter.com/finansakrobat/status/5528316>)
— financial acrobat (@finansakrobat)
January 7, 2015
(<https://twitter.com/mims/statuses/5528316>)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.